Arizona lab studies drug candidates for rare pediatric disorders
An October 12 AWS report describes an eight-person laboratory at the University of Arizona College of Medicine–Phoenix researching existing drugs for rare neurodevelopmental disorders. The team derives RNA signatures from sequencing data and matches them against NIH datasets of approved compounds.
Source review period:
Published: · Updated:
The source does not state the event date; the period shown is the source review period.
The research pipeline combines four AWS services, including HealthOmics, SageMaker AI and Bedrock; researchers prioritize candidates with literature and models. AWS reports that the lab used Amazon Quick Research to cut one literature synthesis from hours of manual reading to 10–15 minutes. These remain research candidates; no clinically proven treatment was reported.
Data
Arizona lab studies drug candidates for rare pediatric disorders
Arizona lab studies drug candidates for rare pediatric disorders
- · Occurred
Source publication date
An October 12 AWS report describes an eight-person laboratory at the University of Arizona College of Medicine–Phoenix researching existing drugs for rare neurodevelopmental disorders. The team derives RNA signatures from sequencing data and matches them against NIH datasets of approved compounds.
Methodology
A source-reported technical account; not an independent experiment.
Updated:
Subjects and places
Subject proposals
- Science and technologySuggested
- Preserved editorial category/topic; broad candidate onlyaws.amazon.com ↗